CTLA4 and neoplasm: More recently, Özdemir et al demonstrated that targeted depletion of immunosuppressive α‐SMA+ CAFs in a genetic PDAC model (PKT: Ptf1acre/+;LSL‐KrasG12D/+;Tgfbr2flox/flox) resulted in reduced fibrosis and accelerated tumour growth [25]; this was, however, accompanied by significant sensitisation to anti‐CTLA‐4 immunotherapy, with survival dramatically prolonged in comparison to non‐CAF‐depleted controls.